Literature DB >> 24418705

Purine receptor P2Y6 mediates cellular response to γ-ray-induced DNA damage.

Shunta Ide1, Naoko Nishimaki, Mitsutoshi Tsukimoto, Shuji Kojima.   

Abstract

We previously showed that nucleotide P2 receptor agonists such as ATP and UTP amplify γ-ray-induced focus formation of phosphorylated histone H2A variant H2AXH2AX), which is considered to be an indicator of DNA damage so far, by activating purine P2Y6 and P2Y12 receptors. Therefore, we hypothesized that these P2 receptors play a role in inducing the repair response to γ-ray-induced DNA damage. In the present study, we tested this idea by using human lung cancer A549 cells. First, reverse-transcription polymerase chain reaction (RT-PCR) showed that P2Y6 receptor is highly expressed in A549 cells, but P2Y12 receptor is only weakly expressed. Next, colony formation assay revealed that P2Y6 receptor antagonist MRS2578 markedly reduced the survival rate of γ-ray-exposed A549 cells. The survival rate was also significantly reduced in P2Y6-knock-down cells, compared with scramble siRNA-transfected cells. Since it has reported that phosphorylation of ERK1/2 after activation of EGFR via P2Y6 and P2Y12 receptors is involved in the repair response to γ-ray-induced DNA damage, we next examined whether γ-ray-induced phosphorylation of ERK1/2 was also inhibited by MRS2578 in A549 cells. We found that it was. Taken together, these findings indicate that purinergic signaling through P2Y6 receptor, followed by ERK1/2 activation, promotes the cellular repair response to γ-ray-induced DNA damage.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24418705     DOI: 10.2131/jts.39.15

Source DB:  PubMed          Journal:  J Toxicol Sci        ISSN: 0388-1350            Impact factor:   2.196


  7 in total

Review 1.  Targeting purinergic pathway to enhance radiotherapy-induced immunogenic cancer cell death.

Authors:  Xuhui Bao; Liyi Xie
Journal:  J Exp Clin Cancer Res       Date:  2022-07-15

2.  Potentiating Cancer Immune Therapy via Nanomaterials and Purinergic Signaling.

Authors:  Davide Ferrari; Stefania Gessi; Stefania Merighi; Manuela Nigro; Alessia Travagli; Jorge S Burns
Journal:  Front Cell Dev Biol       Date:  2022-05-04

Review 3.  The Purinergic Landscape of Non-Small Cell Lung Cancer.

Authors:  Serena Janho Dit Hreich; Jonathan Benzaquen; Paul Hofman; Valérie Vouret-Craviari
Journal:  Cancers (Basel)       Date:  2022-04-11       Impact factor: 6.575

4.  Extracellular ATP protects endothelial cells against DNA damage.

Authors:  Joonas Aho; Mikko Helenius; Sanna Vattulainen-Collanus; Tero-Pekka Alastalo; Juha Koskenvuo
Journal:  Purinergic Signal       Date:  2016-03-31       Impact factor: 3.765

Review 5.  P2Y receptors for extracellular nucleotides: Contributions to cancer progression and therapeutic implications.

Authors:  Lucas T Woods; Kevin Muñoz Forti; Vinit C Shanbhag; Jean M Camden; Gary A Weisman
Journal:  Biochem Pharmacol       Date:  2021-01-04       Impact factor: 5.858

6.  Role of ATP as a Key Signaling Molecule Mediating Radiation-Induced Biological Effects.

Authors:  Shuji Kojima; Yasuhiro Ohshima; Hiroko Nakatsukasa; Mitsutoshi Tsukimoto
Journal:  Dose Response       Date:  2017-02-15       Impact factor: 2.658

Review 7.  Emerging roles of purinergic signaling in anti-cancer therapy resistance.

Authors:  Michele Zanoni; Anna Pegoraro; Elena Adinolfi; Elena De Marchi
Journal:  Front Cell Dev Biol       Date:  2022-09-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.